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Abstract: We recently reported that isoflurane conditioning provided multifaceted protection against
subarachnoid hemorrhage (SAH)-induced delayed cerebral ischemia (DCI), and this protection was
through the upregulation of endothelial nitric oxide synthase (eNOS). SIRT1, an NAD-dependent
deacetylase, was shown to be one of the critical regulators of eNOS. The aim of our current study is
to examine the role of SIRT1 in isoflurane conditioning-induced neurovascular protection against
SAH-induced DCI. Mice were divided into four groups: sham, SAH, or SAH with isoflurane conditioning (with and without EX-527). Experimental SAH via endovascular perforation was performed.
Anesthetic conditioning was performed with isoflurane 2% for 1 h, 1 h after SAH. EX-527, a selective
SIRT1 inhibitor, 10 mg/kg was injected intraperitoneally immediately after SAH in the EX-527 group.
SIRT1 mRNA expression and activity levels were measured. Vasospasm, microvessel thrombosis,
and neurological outcome were assessed. SIRT1 mRNA expression was downregulated, and no
difference in SIRT1 activity was noted after isoflurane exposure. Isoflurane conditioning with and
without EX-527 attenuated vasospasm, microvessel thrombosis and improved neurological outcomes.
Our data validate our previous findings that isoflurane conditioning provides strong protection
against both the macro and micro vascular deficits induced by SAH, but this protection is likely not
mediated through the SIRT1 pathway.
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1. Introduction
Aneurysmal subarachnoid hemorrhage (SAH) is a severe form of stroke with extremely high morbidity and mortality [1], much of which stems from a secondary brain
injury process called delayed cerebral ischemia (DCI) [2]. For years, DCI was solely attributed to vasospasm, which is characterized by large artery narrowing 4–12 d after
SAH [3]. However, in recent years, several additional processes affecting the microcirculation have been causally linked to DCI, including autoregulatory dysfunction [4,5]
and microvessel thrombosis [6,7]. Several therapies have been tried and failed to treat
DCI, which is likely due to targeting individual elements of what has proven to be a
multifactorial process. So, future therapies should be designed to target both large artery
vasospasm and microcirculatory deficits to be effective. To address this issue, we and others
have applied a therapeutic strategy—conditioning—that leverages endogenous molecular
mechanisms to exert a powerful and remarkably pleiotropic protective effect against DCI
after SAH. For years, neurons were felt to be the principal target of this response (neuronal
conditioning) [8], but multiple lines of evidence now show that glia (glial conditioning) [9]
and vessels (vascular conditioning) [10–15] are also causally involved. The latter is of
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thetic conditioning-induced DCI protection after SAH may also be critically dependent on
SIRT1. Hence, our current study is focused on investigating the role of SIRT1 in isoflurane
2.
Results
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2.1. SIRT1 mRNA Expression and Activity after Isoflurane Conditioning in Naive Animals:
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(glial conditioning) [9] and vessels (vascular conditioning) [10–15] are also causally
involved. The latter is of special interest for SAH, given the central role vascular deficits
(vasospasm, autoregulatory dysfunction, and microvessel thrombi) play in DCI [3–7]. This
vascular protection—along with the 4–12 d window between SAH and DCI—makes
SAH
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the SAH group and none died in the sham group. Animals subjected to SAH surgery
were found to have SAH at the ventral surface of the brain at the time of animal sacrifice,
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although the role of SIRT1 on anesthetic conditioning-induced DCI protection in SAH has
yet to be examined.
Our data show that brief exposure to 2% isoflurane significantly downregulated
SIRT1 gene expression but had no significant impact on SIRT1 activity. These results are
consistent with past reports showing that isoflurane significantly downregulates SIRT1
gene and protein expression in mice [45,46]. Similar results have been reported with
another inhalational anesthetic, sevoflurane [47,48].
Our data also show that brief exposure to 2% isoflurane beginning one hour after
SAH induction protects against one key element of DCI—large artery vasospasm, which
is consistent with our past results [15]. In addition, we show that isoflurane conditioning
protects against another critical component of DCI—microvessel thrombosis. These data
provide strong evidence that isoflurane conditioning induces robust protection against
both macro- and micro-vessel components of DCI, leading to improved short-term neurological outcome. A therapeutic strategy that can attenuate both macro- and micro-vessel
dysfunction has great translational potential for SAH patients.
Next, we examined if administration of a highly selective SIRT1 inhibitor, EX-527 [49],
abolishes the DCI protection afforded by isoflurane conditioning. Interestingly, the administration of EX-527 did not eliminate isoflurane conditioning-induced protection against
vasospasm, microvessel thrombosis, or neurological deficits. These results, along with our
observations regarding the impact of isoflurane on SIRT1 gene expression and activity,
indicate that isoflurane-induced DCI protection in SAH is not dependent on SIRT1.
In total, our findings indicate that isoflurane conditioning-induced protection against
vasospasm and microvessel thrombosis after SAH is not mediated through SIRT1. Understanding the molecular underpinnings of anesthetic conditioning-based neurovascular
protection in SAH is critical, as this strategy has a great translational potential given that
isoflurane and other commonly used anesthetic agents are already approved by the FDA
for use in patients and have shown to possess excellent safety profile.
Limitations of the study: Our study has several limitations. (1) SAH in our experiments
were confirmed by the occurrence of apnea after perforation and by the presence of blood
during the animal sacrifice. However, we did not quantify the severity of SAH, and it
is possible that the severity of SAH in the animals were not homogenously distributed.
(2) Though EX-527 is a highly specific SIRT1 inhibitor, it is possible that other SIRT1
inhibitors may have different effects on isoflurane conditioning in SAH-induced DCI.
(3) While we show that Sirt1 may not be involved in isoflurane conditioning induced DCI
protection, the mechanism behind its protection is not explored in the current study.
4. Materials and Methods
4.1. Experimental Animals
Experiments in the study were approved by Washington University in Saint Louis
animal care and use committee (protocol no. 20180080, Approval date: 07/22/2019).
C57BL/6J male mice (12 weeks old) were acquired from Jackson laboratories (Bar Harbor,
ME) for the experiments. Experiments were conducted in a randomized and blinded
manner. Mice underwent sham or SAH surgery and were divided into the following
groups, sham (n = 14), SAH (n = 16), SAH with isoflurane conditioning (n = 19), and
SAH with isoflurane conditioning and EX-527 (n = 18). A separate cohort of mice was
utilized for examining Sirt1 mRNA and activity levels after isoflurane conditioning. A total
of 25 wild-type mice with n = 5 in each group have been utilized for these experiments.
Figure 4 shows the overall experimental design of the study.

Int. J. Mol. Sci. 2021, 22, 4291
Int. J. Mol. Sci. 2021, 22, 4291

6 of 10
6 of 10

Figure
Flow
chart
representing
the
overallexperimental
experimentaldesign.
design.SAH—subarachnoid
SAH—subarachnoid hemorrhage.
Figure
4. 4.
Flow
chart
representing
the
overall
hemorrhage.
Sirt1—silent
type information
Sirt1—silent
mating typemating
information
regulation 2regulation
homolog. 2 homolog.

4.2.
Experimental
SAH
4.2.
Experimental
SAH
Endovascular
perforation
SAH
was
performed
our
published
methods
[14,15].
Endovascular
perforation
SAH
was
performed
perper
our
published
methods
[14,15].
Briefly,
mice
were
anesthetized
with
isoflurane
(4%
induction,
1.5%
maintenance)
in
room
Briefly, mice were anesthetized with isoflurane (4% induction,
1.5% maintenance) in room
◦ C. A midline incision was made in the
air
with
a
core
body
temperature
maintained
at
37
air with a core body temperature maintained at 37 °C. A midline incision was made in the
neck,the
the external
external carotid
(ECA)
waswas
exposed,
and aand
5-0 nylon
introduced
neck,
carotidartery
artery
(ECA)
exposed,
a 5-0suture
nylonwas
suture
was
through it and advanced distally through the internal carotid artery (ICA) until reaching the
introduced through it and advanced distally through the internal carotid artery (ICA)
ICA bifurcation. The suture was advanced further to induce SAH and then removed, and
until reaching the ICA bifurcation. The suture was advanced further to induce SAH and
the ECA was ligated. Mice undergoing sham operation underwent the same steps except
then removed, and the ECA was ligated. Mice undergoing sham operation underwent the
for perforation. Post-surgery, mice were returned to their cages when fully recovered.
same steps except for perforation. Post-surgery, mice were returned to their cages when
fully
4.3.recovered.
Isoflurane Conditioning
Mice were administered 2% isoflurane in room air for one hour, beginning one-hour
4.3. Isoflurane Conditioning
post SAH surgery. Sham mice were administered room air for one hour without isoflurane.
Mice were
administered
2%
isofluraneusing
in room
airanalyzer
for one (Datex
hour, beginning
Isoflurane
concentration
was
monitored
a gas
Ohmeda, one-hour
Capnomac
◦
post
SAH
surgery.
Sham
mice
were
administered
room
air
for
one
hour
Ultima, Louisville, KY, USA). A normal body temperature at 37 C was maintainedwithout
utilizing
isoflurane.
Isofluraneblanket.
concentration was monitored using a gas analyzer (Datex Ohmeda,
the homeothermic
Capnomac Ultima, USA). A normal body temperature at 37 °Cwas maintained utilizing
EX-527 (a Selective
SIRT1 Inhibitor) Treatment
the4.4.
homeothermic
blanket.
To examine the role of SIRT1 in isoflurane conditioning-induced neurovascular protec4.4.
EX-527
(a Selective
SIRT1
Inhibitor)
Treatment
tion,
a separate
cohort
of animals
were
injected intraperitoneally with EX-527 (10 mg/kg,
To examine
roleLouis,
of SIRT1
in isoflurane
conditioning-induced
neurovascular
Millipore
Sigma,the
Saint
MO, USA)
diluted with
DMSO+1.2% cyclodextrin+PBS1X
immediately
after SAH
induction.
three groups
received equal
amounts
protection,
a separate
cohort
of animalsAnother
were injected
intraperitoneally
with EX-527
(10of
DMSO+1.2%
cyclodextrin+PBS1X
withoutdiluted
EX-527 as
the control
solution.
mg/kg,
Millipore
Sigma, Saint intraperitoneally
Louis, MO, USA)
with
DMSO+1.2%
cyclodextrin+PBS1X immediately after SAH induction. Another three groups received
4.5. Vasospasm
equal
amounts ofAssessment
DMSO+1.2% cyclodextrin+PBS1X intraperitoneally without EX-527 as
Vasospasm
assessment was performed per our published methods using ROX SE, 72
the control solution.
h after SAH surgery. [50] Briefly, mice were anesthetized, transcardially perfused with PBS
1×Vasospasm
, 10% formalin,
and ROX-SE. Blood vessels in the circle of Willis were imaged under a
4.5.
Assessment
fluorescent
microscope
using
CCD camera
SNAP EZ,
Photometrics,
Tucson,
AZ,
Vasospasm assessment
wasaperformed
per(Cool
our published
methods
using ROX
SE, 72
® software (Universal Imaging, West Chester, PA, USA). Vasospasm
USA)
and
MetaMorph
h after SAH surgery. [50] Briefly, mice were anesthetized, transcardially perfused with
measurement
for eachand
brain
sampleBlood
was obtained
bythe
recording
narrowest
diameter
PBS
1X, 10% formalin,
ROX-SE.
vessels in
circle ofthe
Willis
were imaged
within
the
first
1000
µm
segment
of
the
left
(ipsilateral)
MCA.
under a fluorescent microscope using a CCD camera (Cool SNAP EZ, Photometrics,

Tucson, AZ, USA) and MetaMorph® software (Universal Imaging, West Chester, PA,

Int. J. Mol. Sci. 2021, 22, 4291

7 of 10

4.6. Neurobehavioral Assessment
According to our previously published protocol [14,15], neurobehavioral outcome
was examined baseline and for next three days after SAH. Briefly, neurological function
was graded based on a motor score (0–12) and a sensory score (4–12) that assessed spontaneous activity, symmetry of limb movements, climbing, balance and coordination body
proprioception and vibrissa, visual, and tactile responses.
4.7. Microvessel Thrombosis Assessment
Cortical microvessel thrombosis was assessed by immunofluorescence staining for
fibrinogen. Briefly, brain samples fixed in 4% paraformaldehyde were sectioned into 50 µm
coronal sections. Brain sections were incubated with a blocking buffer (0.1% Triton X-100
TBS-T with 0.2% milk and 1% BSA) and then incubated with rabbit anti-fibrinogen antibody
(1:3000, Abcam, Cambridge, MA, USA) overnight at 4 ◦ C, followed by incubation with
donkey anti-rabbit secondary antibody (1:2000, Invitrogen Waltham, MA, USA), overnight
at 4 ◦ C Sections mounted on the slide were analyzed for the fibrinogen staining under
NanoZoomer 2.0-HT digital slide scanner (Hamamatsu Corporation, Bridgewater, NJ,
USA). The microvessel thrombosis density was calculated with Image J.
4.8. Quantitative Polymerase Chain Reaction (qPCR) for SIRT1 Gene Expression
Isoflurane-induced changes in the SIRT1 mRNA expression were measured by TaqMan®
qPCR assay. Total RNA was prepared from cerebral cortex using RNeasy mini kit (Qiagen)
and converted to cDNA using a SuperScript® IV VILO™ master mix kit (Invitrogen) according
to the manufacturer’s instructions. Template cDNA (25 ng) was combined with a ready-to-use
TaqMan Fast Advanced qPCR Master Mix (ThermoFisher Scientific, Waltham, MA, USA)
for gene expression experiments with a custom TaqMan® Sirt1 probe. Thermal cycling
was performed in 7500 Fast Real-Time PCR System (Applied Biosystems® , Foster City, CA,
USA), and the threshold cycle (Ct) values for all samples were calculated using proprietary
software. Relative mRNA expression, normalized to the geometric mean of 2 reference genes
(gapdh and actb), was calculated using the 2−∆∆CT method with sex-matched control samples
as reference.
4.9. Enzyme-Linked Immunosorbent Assay (ELISA) for SIRT1 Protein Expression
Protein lysates were prepared from approximately 60 mg of cerebral cortex, and
protein concentrations were determined using BCA Protein Assay Kit (ThermoFisher
Scientific Inc., Waltham, MA, USA), and stored at −80 ◦ C freezer until further use. SIRT1
activity was measured using a Sirtuin Activity Assay Kit (catalog # K324-100, Bio Vision
Inc., Milpitas, CA, USA) according to the manufacturer’s instructions. All samples were
performed in duplicate, and fluorescence intensity was read at Ex 400 nm/Em 505 in end
point mode with Tecan Infinite® M200 PRO multimode plate reader. Results calculated
from the standard curve for SIRT1 activity were expressed as mU/mg total brain protein.
4.10. Statistical Analysis
Power analysis for individual experiments were calculated based on our pilot studies
and previous published studies. For Sirt1 mRNA levels and protein activity, we estimate
80% power to detect 20% difference between groups with an n = 5 per group based on a
one-way ANOVA model at a significance level of 5%. When comparing vasospasm and
neurological outcome, we estimate 80% power to detect 50% difference between groups
with n = 14–18 per group based on a one-way ANOVA model at a significance level of
5%. For microvessel thrombosis, we estimate 80% power to detect 25% difference between
groups with n = 5–8 per group, based on two-way ANOVA models without interaction
at a significance level of 5%. Data are represented as the mean ± SEM. ANOVA with
Newman–Keuls multiple comparison test was utilized to analyze large artery vasospasm,
microvessel thrombosis, SIRT1 gene expression, and protein activity. Two-way repeated

Int. J. Mol. Sci. 2021, 22, 4291

8 of 10

measures ANOVA followed by a Newman–Keuls multiple comparison test was used to
analyze neurological outcome. p < 0.05 was considered statistically significant.
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